Literature DB >> 20219616

Determinants of renal disease variability in ADPKD.

Peter C Harris1, Sandro Rossetti.   

Abstract

In common with other Mendelian diseases, the presentation and progression of autosomal dominant polycystic kidney disease (ADPKD) vary widely in the population. The typical course is of adult-onset disease with ESRD in the 6th decade. However, a small proportion has adequate renal function into the 9th decade, whereas others present with enlarged kidneys as neonates. ADPKD is genetically heterogeneous, and the disease gene is a major determinant of severity; PKD1 on average is associated with ESRD 20 years earlier than PKD2. The majority of PKD1 and PKD2 mutations are likely fully inactivating although recent studies indicate that some alleles retain partial activity (hypomorphic alleles). Homozygotes for such alleles are viable and in combination with an inactivating allele can result in early-onset disease. Hypomorphic alleles and mosaicism may also account for some cases with unusually mild disease. The degree of phenotypic variation detected in families indicates that genetic background influences disease severity. Genome-wide association studies are planned to map common variants associated with severity. Although ADPKD is a simple genetic disease, fully understanding the phenotypic variability requires consideration of influences at the genic, allelic, and genetic background level, and so, ultimately, it is complex. 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219616      PMCID: PMC2837603          DOI: 10.1053/j.ackd.2009.12.004

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  103 in total

Review 1.  Massively parallel sequencing: the next big thing in genetic medicine.

Authors:  Tracy Tucker; Marco Marra; Jan M Friedman
Journal:  Am J Hum Genet       Date:  2009-08       Impact factor: 11.025

2.  Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.

Authors:  Thomas Schnelldorfer; Vicente E Torres; Shaheen Zakaria; Charles B Rosen; David M Nagorney
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

3.  Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Authors:  Mark B Consugar; Wai C Wong; Patrick A Lundquist; Sandro Rossetti; Vickie J Kubly; Denise L Walker; Laureano J Rangel; Richard Aspinwall; W Patrick Niaudet; Seza Ozen; Albert David; Milen Velinov; Eric J Bergstralh; Kyongtae T Bae; Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Julian R Sampson; Brian D Dawson; Peter C Harris
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

Review 4.  Mouse models of polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  Curr Top Dev Biol       Date:  2008       Impact factor: 4.897

5.  Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Authors:  Hester Happé; Wouter N Leonhard; Annemieke van der Wal; Bob van de Water; Irma S Lantinga-van Leeuwen; Martijn H Breuning; Emile de Heer; Dorien J M Peters
Journal:  Hum Mol Genet       Date:  2009-04-28       Impact factor: 6.150

6.  Polycystin-1 and -2 dosage regulates pressure sensing.

Authors:  Reza Sharif-Naeini; Joost H A Folgering; Delphine Bichet; Fabrice Duprat; Inger Lauritzen; Malika Arhatte; Martine Jodar; Alexandra Dedman; Franck C Chatelain; Uwe Schulte; Kevin Retailleau; Laurent Loufrani; Amanda Patel; Frederick Sachs; Patrick Delmas; Dorien J M Peters; Eric Honoré
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

7.  Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease.

Authors:  Ying-Cai Tan; Jon D Blumenfeld; Raluca Anghel; Stephanie Donahue; Rimma Belenkaya; Marina Balina; Thomas Parker; Daniel Levine; Debra G B Leonard; Hanna Rennert
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

8.  Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.

Authors:  Berenice Reed; Kim McFann; William J Kimberling; York Pei; Patricia A Gabow; Karen Christopher; Eric Petersen; Catherine Kelleher; Pamela R Fain; Ann Johnson; Robert W Schrier
Journal:  Am J Kidney Dis       Date:  2008-07-21       Impact factor: 8.860

Review 9.  The diversity of PKD1 alleles: implications for disease pathogenesis and genetic counseling.

Authors:  Richard N Sandford
Journal:  Kidney Int       Date:  2009-04       Impact factor: 10.612

10.  Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

Authors:  Sandro Rossetti; Vickie J Kubly; Mark B Consugar; Katharina Hopp; Sushmita Roy; Sharon W Horsley; Dominique Chauveau; Lesley Rees; T Martin Barratt; William G van't Hoff; Patrick Niaudet; W Patrick Niaudet; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-01-21       Impact factor: 10.612

View more
  24 in total

Review 1.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

2.  Type of PKD1 mutation influences renal outcome in ADPKD.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Jian-Min Chen; Maryvonne Hourmant; Marie-Pascale Morin; Régine Perrichot; Christophe Charasse; Bassem Whebe; Eric Renaudineau; Philippe Jousset; Marie-Paule Guillodo; Anne Grall-Jezequel; Philippe Saliou; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

3.  Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.

Authors:  Hirayasu Kai; Yuki Shinozaki; Airi Nishikubo; Megumi Watanabe; Takashi Tawara; Mamiko Iwase; Ryouya Tsunoda; Noriaki Moriyama; Toshiaki Usui; Tetsuya Kawamura; Kei Nagai; Masahiro Hagiwara; Chie Saito; Naoki Morito; Joichi Usui; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2015-11-17

Review 4.  Proteomic urinary biomarker approach in renal disease: from discovery to implementation.

Authors:  Joost P Schanstra; Harald Mischak
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

5.  Blocking rpS6 Phosphorylation Exacerbates Tsc1 Deletion-Induced Kidney Growth.

Authors:  Huijuan Wu; Jianchun Chen; Jinxian Xu; Zheng Dong; Oded Meyuhas; Jian-Kang Chen
Journal:  J Am Soc Nephrol       Date:  2015-08-21       Impact factor: 10.121

6.  Mutations in PAX2 associate with adult-onset FSGS.

Authors:  Moumita Barua; Emilia Stellacci; Lorenzo Stella; Astrid Weins; Giulio Genovese; Valentina Muto; Viviana Caputo; Hakan R Toka; Victoria T Charoonratana; Marco Tartaglia; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

7.  Inactivation of integrin-β1 prevents the development of polycystic kidney disease after the loss of polycystin-1.

Authors:  Kyung Lee; Sylvia Boctor; Laura M C Barisoni; G Luca Gusella
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

8.  Bilineal inheritance of PKD1 abnormalities mimicking autosomal recessive polycystic disease.

Authors:  Rodney D Gilbert; Priya Sukhtankar; Katherine Lachlan; Darren J Fowler
Journal:  Pediatr Nephrol       Date:  2013-04-28       Impact factor: 3.714

9.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Authors:  María V Irazabal; Laureano J Rangel; Eric J Bergstralh; Sara L Osborn; Amber J Harmon; Jamie L Sundsbak; Kyongtae T Bae; Arlene B Chapman; Jared J Grantham; Michal Mrug; Marie C Hogan; Ziad M El-Zoghby; Peter C Harris; Bradley J Erickson; Bernard F King; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

Review 10.  X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure.

Authors:  A Pierides; K Voskarides; M Kkolou; M Hadjigavriel; C Deltas
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.